Harold Burstein, MD, PhD

Articles

MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

June 29th 2022

Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.

MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy

June 29th 2022

Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.

PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy

June 22nd 2022

Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.

Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer

June 22nd 2022

Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.

HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium

June 15th 2022

Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.

Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer

June 15th 2022

Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.

Dr. Burstein Discusses Key Updates from the SOFT Trial

December 9th 2017

Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial.

Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

May 9th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer.